These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 17023244)
1. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. Kim DY; Park CI; Ohn SH; Moon JY; Chang WH; Park SW Arch Phys Med Rehabil; 2006 Oct; 87(10):1346-51. PubMed ID: 17023244 [TBL] [Abstract][Full Text] [Related]
2. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Elovic EP; Brashear A; Kaelin D; Liu J; Millis SR; Barron R; Turkel C Arch Phys Med Rehabil; 2008 May; 89(5):799-806. PubMed ID: 18452724 [TBL] [Abstract][Full Text] [Related]
3. Long-lasting effect of a single botulinum toxin injection in the treatment of oropharyngeal dysphagia secondary to upper esophageal sphincter dysfunction: a pilot study. Terre R; Valles M; Panades A; Mearin F Scand J Gastroenterol; 2008; 43(11):1296-303. PubMed ID: 18649151 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Alberty J; Oelerich M; Ludwig K; Hartmann S; Stoll W Laryngoscope; 2000 Jul; 110(7):1151-6. PubMed ID: 10892687 [TBL] [Abstract][Full Text] [Related]
5. Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Mayer NH; Whyte J; Wannstedt G; Ellis CA Arch Phys Med Rehabil; 2008 May; 89(5):982-7. PubMed ID: 18452749 [TBL] [Abstract][Full Text] [Related]
6. Cricopharyngeal myotomy normalizes the opening size of the upper esophageal sphincter in cricopharyngeal dysfunction. Yip HT; Leonard R; Kendall KA Laryngoscope; 2006 Jan; 116(1):93-6. PubMed ID: 16481817 [TBL] [Abstract][Full Text] [Related]
7. Design and implementation of botulinum toxin on cricopharyngeal dysfunction guided by a combination of catheter balloon, ultrasound, and electromyography (BECURE) in patients with stroke: study protocol for a randomized, double-blinded, placebo-controlled trial. Xie M; Dou Z; Wan G; Zeng P; Wen H Trials; 2021 Mar; 22(1):238. PubMed ID: 33789722 [TBL] [Abstract][Full Text] [Related]
8. Cortical somatosensory evoked potentials and spasticity assessment after botulinum toxin type A injection in children with cerebral palsy. Boćkowski L; Okurowska-Zawada B; Sobaniec W; Kułak W; Sendrowski K Adv Med Sci; 2007; 52 Suppl 1():171-5. PubMed ID: 18229658 [TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Turkel CC; Bowen B; Liu J; Brin MF Arch Phys Med Rehabil; 2006 Jun; 87(6):786-92. PubMed ID: 16731213 [TBL] [Abstract][Full Text] [Related]
10. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Tsai SJ; Ying TH; Huang YH; Cheng JW; Bih LI; Lew HL Arch Phys Med Rehabil; 2009 May; 90(5):832-6. PubMed ID: 19406304 [TBL] [Abstract][Full Text] [Related]
11. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291 [TBL] [Abstract][Full Text] [Related]
12. The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Scholtes VA; Dallmeijer AJ; Knol DL; Speth LA; Maathuis CG; Jongerius PH; Becher JG Arch Phys Med Rehabil; 2006 Dec; 87(12):1551-8. PubMed ID: 17141633 [TBL] [Abstract][Full Text] [Related]
13. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Giovannelli M; Borriello G; Castri P; Prosperini L; Pozzilli C Clin Rehabil; 2007 Apr; 21(4):331-7. PubMed ID: 17613573 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study. Lew HL; Lee EH; Castaneda A; Klima R; Date E Arch Phys Med Rehabil; 2008 Jan; 89(1):75-80. PubMed ID: 18164334 [TBL] [Abstract][Full Text] [Related]
15. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. Sahai A; Dowson C; Khan MS; Dasgupta P BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019 [TBL] [Abstract][Full Text] [Related]
16. The use of a portable muscle tone measurement device to measure the effects of botulinum toxin type a on elbow flexor spasticity. Chen JJ; Wu YN; Huang SC; Lee HM; Wang YL Arch Phys Med Rehabil; 2005 Aug; 86(8):1655-60. PubMed ID: 16084822 [TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin treatment for oropharyngeal dysphagia in patients with stroke. Terré R; Panadés A; Mearin F Neurogastroenterol Motil; 2013 Nov; 25(11):896-e702. PubMed ID: 23991889 [TBL] [Abstract][Full Text] [Related]
18. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Wallen M; O'Flaherty SJ; Waugh MC Arch Phys Med Rehabil; 2007 Jan; 88(1):1-10. PubMed ID: 17207668 [TBL] [Abstract][Full Text] [Related]